#HVO hVIVO – H1 TRADING UPDATE July 22, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provides an unaudited trading update for the six months ended 30 June 2025 (H1 2025).   Highlights ·    Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year ·    EBITDA margin (pre-exceptionals) of c.12% (H1 2024: 24.5%) ·    Cash of £23.3 million as at 30 June 2025 (30 June…

Continue reading